Featured Research

from universities, journals, and other organizations

Immune Reaction At Tumour Site Determines Clinical Outcome In Patients With Colorectal Cancer

Date:
September 15, 2009
Source:
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology
Summary:
The immune reaction at tumour site determines cancer evolution and clinical outcome in patients with colorectal cancer, regardless of the local extent and spread of the tumour, according to new findings. The analysis of immunological parameters should therefore be integrated into the process of staging and clinical decision finding, one of the researchers says.

The immune reaction at tumour site determines cancer evolution and clinical outcome in patients with colorectal cancer, regardless of the local extent and spread of the tumour, according to the findings of Jιrτme Galon, INSERM Research Director, Paris, and co-workers. The analysis of immunological parameters should therefore be integrated into the process of staging and clinical decision finding, says Galon at the 2nd European Congress of Immunology ECI 2009.

Colorectal cancer is one of the most common malignancies, with an estimated annual incidence of one million cases worldwide. The prognosis is severe, with a 5-year-survival of 55 %. Surgical resection is effective for localized disease. An additional post-surgical course of chemotherapy is reserved for patients with lymph node or distant metastases. But also a significant proportion of patients with local disease (Stage I/II patients) develops recurrence and dies from the disease. “There is clearly a need to identify novel predictive factors to identify patients with the potential for colon cancer progression,” Galon stresses.

Actually, assessing patient survival and choosing the optimal therapy are based on the currently used classification. Staging includes tumour size, local spread and distant metastases. Galon und co-workers showed that a detailed analysis of local immune reaction would be a better predictor, especially in identifying high risk patients with minimal invasive tumours.

Galon analysed the infiltration of lymphocytes, the most important cells of immune response, into the tumour and peritumoural tissue in 415 patients with colorectal cancer. The scientist developed a comprehensive analysis of the nature, the functional orientation, the density and the organization of the immune cell populations within the tumour. He performed a large-scale analysis of in situ immune parameters as well as an original analysis of gene expression, which enables the identification of genes whose co-expression is correlated with cancer evolution. These data were confirmed in a blinded manner in two independent patient cohorts (n= 60 and n= 119) from different hospitals.

All statistical analyses reveal the strength of the in situ immune contexture on clinical outcome at all stages of the disease. High density of immune cells correlated with an equally favourable prognosis regardless of the cancer size and spread. Conversely, a weak immune response correlated with a very poor prognosis even in patients with minimal tumour invasion. "This has never been shown in any human tumour“, says Galon. As a consequence this should lead to recast the currently used classification of colorectal cancers for predicting clinical outcome, and refine the patient groups that are at high-risk of tumour recurrence that may benefit from adjuvant theapy, including immunotherapy.

Recent data of 602 stage I-II patients with colorectal cancer from two independent cohorts emphasize the crucial role of two T cell populations: the cytotoxic (CD8) and the memory T cells. Memory T cells obviously control the early steps of the metastatic process. They may have a central role in the control of tumour spreading along lymphovascular and perineural structures, but also to lymph nodes or distant organs. The function of these immune cells is relevant for the recurrence risk and patient survival, even in very small tumours. Galon und colleagues developed a simple "immune score“ method, which may be of clinical value for the identification of high-risk patients.


Story Source:

The above story is based on materials provided by Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. Note: Materials may be edited for content and length.


Cite This Page:

Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. "Immune Reaction At Tumour Site Determines Clinical Outcome In Patients With Colorectal Cancer." ScienceDaily. ScienceDaily, 15 September 2009. <www.sciencedaily.com/releases/2009/09/090915101639.htm>.
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. (2009, September 15). Immune Reaction At Tumour Site Determines Clinical Outcome In Patients With Colorectal Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/09/090915101639.htm
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. "Immune Reaction At Tumour Site Determines Clinical Outcome In Patients With Colorectal Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/09/090915101639.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins